Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vrachatis DA
- Papathanasiou KA
- Kazantzis D
- Giotaki SG
- Raisakis K
- Kaoukis A
- Kossyvakis C
- Deftereos G
- Reimers B
- Avramides D
- Siasos G
- Cleman M
- Giannopoulos G
- Lansky A
- Deftereos S
Grupos
Abstract
Isolated coronary artery ectasia (CAE) is a relatively rare clinical entity, the pathogenesis of which is poorly understood. More and more evidence is accumulating to suggest a critical inflammatory component. We aimed to elucidate any association between neutrophil to lymphocyte ratio and coronary artery ectasia. A systematic MEDLINE database, ClinicalTrials.gov, medRxiv, Scopus and Cochrane Library search was conducted: 50 studies were deemed relevant, reporting on difference in NLR levels between CAE patients and controls (primary endpoint) and/or on high-sensitive CRP, IL-6, TNF-a and RDW levels (secondary endpoint), and were included in our final analysis. (PROSPERO registration number: CRD42021224195). All inflammatory biomarkers under investigation were found higher in coronary artery ectasia patients as compared to healthy controls (NLR; SMD = 0.73; 95% CI: 0.27-1.20, hs-CRP; SMD = 0.96; 95% CI: 0.64-1.28, IL-6; SMD = 2.68; 95% CI: 0.95-4.41, TNF-a; SMD = 0.50; 95% CI: 0.24-0.75, RDW; SMD = 0.56; 95% CI: 0.26-0.87). The main limitations inherent in this analysis are small case-control studies of moderate quality and high statistical heterogeneity. Our findings underscore that inflammatory dysregulation is implicated in coronary artery ectasia and merits further investigation.
Datos de la publicación
- ISSN/ISSNe:
- 2075-4418, 2075-4418
- Tipo:
- Article
- Páginas:
- -
- Factor de Impacto:
- 0,658 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
DIAGNOSTICS MDPI AG
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- biomarkers; coronary artery ectasia; inflammation; neutrophil lymphocyte ratio
Proyectos asociados
MECANISMOS DE ENFERMEDAD EN LA MIOCARDIOPATIA ARRITMOGENICA, MEJORAS EN SU DIAGNOSTICO Y BUSQUEDA DE DIANAS TERAPEUTICAS.
Investigador Principal: ESTHER ZORIO GRIMA
PI14/01477 . INSTITUTO DE SALUD CARLOS III . 2015
INCORPORACIÓN GRUPOS CIBER. DR. DOLZ
Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ
CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, BASADO EN EVENTOS, QUE COMPARA LA EFICACIA Y SEGURIDAD DE RIVAROXABAN CON PLACEBO EN LA REDUCCIÓN DEL RIESGO DE MUERTE, INFARTO DE MIOCARDIO O ICTUS, EN PACIENTES CON INSUFICIENCIA CARDIACA Y ENFERMEDAD ARTERIAL CORONARIA SIGNIFICATIVA TRAS UN EPISODIO DE INSUFICIENCIA CARDIACA DESCOMPENSADA.
Investigador Principal: LUIS ALMENAR BONET
RIVAROXHFA3001/BAY59-7939/16302 . 2013
EVALUACIÓN, EN PACIENTES CON PROCESOS MÉDICOS, DE RIVAROXABAN FRENTE A PLACEBO EN LA REDUCCIÓN DEL RIESGO DE TROMBOEMBOLISMO VENOSO DESPUÉS DEL ALTA HOSPITALARIA. (MARINER).
Investigador Principal: JOSÉ ANTONIO TODOLÍ PARRA
RIVAROXDVT3002/BAY59-7939/17261
Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.
Investigador Principal: JOSÉ LUIS DÍEZ GIL
BA-SCAD . 2021
ASSESSING THE EFFECT OF DAPAGLIFOZIN ON PLAQUE PROGRESSION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION DAPA-PLACA.
Investigador Principal: JORGE SANZ SÁNCHEZ
DAPA-PLACA . 2021
Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures. DOAC-NOSTOP.
Investigador Principal: JORGE SANZ SÁNCHEZ
DOAC-NOSTOP . 2021
Cita
Vrachatis DA,Papathanasiou KA,Kazantzis D,Sanz J,Giotaki SG,Raisakis K,Kaoukis A,Kossyvakis C,Deftereos G,Reimers B,Avramides D,Siasos G,Cleman M,Giannopoulos G,Lansky A,Deftereos S. Inflammatory Biomarkers in Coronary Artery Ectasia: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2022. 12. (5):1026. IF:3,600. (2).